StockStory flags GE Vernova as promising, Fox and Biogen as underperformers

Industry

โดย StockStory·Read original

Summary · why it matters

StockStory highlights GE Vernova as an S&P 500 stock with promising prospects, while questioning Fox and Biogen. GE Vernova, spun off from General Electric in 2023, is expected to grow sales by 20.4% in the next 12 months, with earnings per share compounding at 223% annually over the past year and free cash flow margin expanding by 41.9 percentage points over four years. Fox faces below-average revenue growth of 5.4% annually over five years and a projected 5.4 percentage point contraction in free cash flow margin. Biogen saw sales decline 4.6% annually over five years and earnings per share fall 11.4% annually, with waning returns on capital.

Fox Corp Class A ▼

GE Vernova LLC ▲

Impact on stocks 3

Biotech & Genomic Medicine▼ · 1 stocks

▼ NegativeCapitalrelevance

Sales declining 4.6% annually and EPS falling 11.4% annually over five years, with waning returns on capital.

Communication Services▼ · 1 stocks

Fox Corp Class A

▼ NegativeCapitalrelevance

Below-average revenue growth of 5.4% annually and projected 5.4 percentage point contraction in free cash flow margin.

Energy Transition & Power Demand▲ · 1 stocks

▲ PositiveCapitalrelevance

Expected 20.4% sales growth, EPS compounding at 223% annually, and free cash flow margin expanding by 41.9 percentage points over four years.